Erik Harris serves as Executive Vice President and Chief Commercial Officer. He joined Ultragenyx in 2017 as Senior Vice President, Head of North American Commercial Operations, and was promoted to Chief Commercial Officer in June 2019. In his current role, he is responsible for all commercial operations in North America, Europe, and Latin America, and is a member of the company’s executive leadership team.
Prior to joining Ultragenyx in 2017, Mr. Harris spent six years at Crescendo Bioscience, a subsidiary of Myriad Genetics, Inc. At Crescendo he held various leadership positions, most recently as Vice President of Commercial, leading all aspects of marketing, sales, managed care and customer service. Mr. Harris previously served as Vice President of Pulmonology Marketing at Intermune, Inc. Earlier in his career he held positions in the commercial organizations at Elan Pharmaceuticals, Inc., Genentech, Inc., and Bristol-Myers Squibb Company. In addition to the Crysvita® and Mepsevii® launches, Mr. Harris has been involved in the launches of Tarceva®, Tysabri® and Vectra-DA®. To begin his professional career, Mr. Harris served as a Lieutenant Commander in Naval Aviation and Congressional Fellow for the United States Navy.
Mr. Harris received his Masters of Business Administration at the Wharton School of Business, and Bachelor of Science at the United States Naval Academy.
What is Erik Harris' net worth?
The estimated net worth of Erik Harris is at least $2.42 million as of September 5th, 2023. Mr. Harris owns 51,281 shares of Ultragenyx Pharmaceutical stock worth more than $2,422,514 as of November 23rd. This net worth evaluation does not reflect any other assets that Mr. Harris may own. Additionally, Mr. Harris receives an annual salary of $878,770.00 as EVP at Ultragenyx Pharmaceutical. Learn More about Erik Harris' net worth.
How old is Erik Harris?
Mr. Harris is currently 53 years old. There are 8 older executives and no younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical is Dr. Emil D. Kakkis M.D., Ph.D., Founder, President, CEO & Director, who is 64 years old. Learn More on Erik Harris' age.
What is Erik Harris' salary?
As the EVP of Ultragenyx Pharmaceutical Inc., Mr. Harris earns $878,770.00 per year. The highest earning executive at Ultragenyx Pharmaceutical is Dr. Emil D. Kakkis M.D., Ph.D., Founder, President, CEO & Director, who commands a salary of $1,460,000.00 per year. Learn More on Erik Harris' salary.
How do I contact Erik Harris?
Has Erik Harris been buying or selling shares of Ultragenyx Pharmaceutical?
Erik Harris has not been actively trading shares of Ultragenyx Pharmaceutical during the past quarter. Most recently, Erik Harris sold 6,000 shares of the business's stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $37.96, for a transaction totalling $227,760.00. Following the completion of the sale, the executive vice president now directly owns 51,281 shares of the company's stock, valued at $1,946,626.76. Learn More on Erik Harris' trading history.
Who are Ultragenyx Pharmaceutical's active insiders?
Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Eric Crombez (Chief Medical Officer and EVP), Mardi Dier (CFO), Matthew Fust (Director), Erik Harris (EVP), Howard Horn (CFO and EVP, Corporate Strategy), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?
During the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 91,799 shares worth more than $4,701,943.08. The most recent insider tranaction occured on October, 10th when CFO Howard Horn sold 7,465 shares worth more than $393,853.40. Insiders at Ultragenyx Pharmaceutical own 5.8% of the company.
Learn More about insider trades at Ultragenyx Pharmaceutical. Information on this page was last updated on 10/10/2024.
